Sunday, 20 November 2011

Keuntungan dan Efek Samping KB IUD


Apakah Bunda berniat mengikuti program Keluarga Berencana (KB)? Kalau ya, mungkin Bunda pernah mendengar beberapa informasi mengenai efek samping KB. Misalnya wajah berjerawat, berat badan bertambah, sulit hamil di kemudian hari dan masih banyak penjelasan lain yang belum tentu benar. Bagaimana dengan KB jenis IUD?

KB IUD adalah alat kontrasepsi Intra Uterine Device (IUD) berbentuk T terbuat dari plastik yang lentur yang akan menghalangi sperma bertemu sel telur sehingga kehamilan tidak akan terjadi. Pada ujung bagian bawahnya terdapat tali yang dimasukkan dalam rahim. Fungsi tali ini adalah untuk mengecek apakah IUD masih terpasang dengan tepat dan baik.  Pemasangan KB IUD ini pun tidak terlalu lama, bisa dilakukan dengan rawat jalan dan sesekali mengontrolnya ke dokter.

Ada dua jenis KB IUD. Pertama KB IUD tembaga (Copper), cara kerjanya dengan melepaskan partikel tembaga yang dapat membunuh sperma sehingga sperma gagal bertemu sel telur. Jenis lainnya yaitu  KB IUD dengan hormon yang melepaskan hormon progestin.

KB IUD ini cenderung aman, tidak mahal dan sangat efektif mencegah kehamilan. Keuntungan KB IUD ini antara lain:
• Bertahan dalam jangka panjang 5-10 tahun
• Tak perlu kuatir lupa seperti layaknya kontrasepsi pil
• Tidak mengganggu program menyusui
• Tidak terasa oleh Bunda mau pun suami saat berhubungan
• Tetap bisa berolahraga, seperti berenang dan jenis olahraga lainnya

Meski memiliki keuntungan yang cukup menggiurkan namun, Bunda perlu mewaspadai efek sampingnya. Efek samping yang biasa terjadi seperti kram dan sakit pinggang setelah beberapa jam pemasangan. Beberapa Bunda mengalami pendarahan ringan dan nyeri setelah beberapa minggu pemasangan. Pada IUD tembaga terkadang volume haid lebih banyak, cairan vagina bertambah dan resiko keputihan lebih besar. Tak perlu kuatir berlebih, yang penting tetaplah berkonsultasi dengan dokter.

Tips :
Lakukan pengecekan sebulan sekali (setelah haid) dengan memasukkan jari ke dalam vagina untuk mengetahui apakah tali IUD masih terpasang atau lepas. Bila terasa tali IUD tidak terpasang atau kendur lakukan pengecekan ke dokter.

Rumus Menghitung Berat Badan ideal

Hampir setiap orang di dunia ini ingin memiliki berat badan yang wajar tidak lebih dan tidak kurang, namun banyak hal dan faktor yang menyebabkan keinginan itu sulit untuk terwujud. Berikut ini adalah rumus cara menghitung berat badan normal dan berat badan yang ideal versi indeks broca. Gunakan timbangan berat badan yang masih berfungsi dengan baik dan akurat.
1. Berat Badan Normal
Berat Badan Normal = Tinggi Badan - 100
Contoh :
Jika tinggi kita dari ujung kaki hingga ujung kepala adalah 160 cm maka berat badan normal kita adalah 160 - 100 = 60 kg.
2. Berat Badan Ideal
Berat Badan Ideal = (Tinggi Badan - 100) - ( 10% tinggi badan -100)
Contohnya : Jika tinggi badan kita adalah setinggi 150 cm, maka berat badan ideal kita adalah (150 - 100) - (10% x (150 - 100) = 50 - 5 = 45 kg.
Dari hasil tersebut dapat kita ketahui apa yang terjadi dengan diri kita dengan membandingkan hasilnya berikut di bawah ini :
- Kelebihan Berat Badan / Overweight = Hasilnya 10% s/d 20% lebih besar
- Kegemukan / Obesitas / Obesity = Hasilnya lebih dari 20% dari yang seharusnya
- Kurus = Hasilnya 10% kurang dari yang seharusnya.
Jika ada kesalahan mohon maaf dan tolong dikoreksi. Thanks.

Saturday, 12 November 2011

Newer 'Pill' May Raise Blood Clot Risk


WEDNESDAY, Oct. 26 (HealthDay News) -- Birth control pills with newer types of progestogen hormones (drospirenone, desogestrel or gestodene) are more likely than others to cause serious blood clots, a new study confirms.
These new pills -- marketed as Yaz or Yasmin, among other brand names, in North America -- are popular, although the risk of serious blood clots, also known as venous thromboembolism (VTE), has been noted before. Last month, the U.S. Food and Drug Administration issued a cautionary note warning of raised odds for blood clots in women taking the newer form of oral contraceptives.
In the new study, researchers reviewed data on all Danish women, ages 15 to 49, not pregnant between January 2001 and December 2009. During that time, over 4,200 first episodes of VTEs occurred.
Women taking birth control pills with a newer progestogen hormone had twice the risk of VTE compared to those who took pills with an older progestogen called levonorgestrel.
Compared to women who did not use birth control pills, the risk of VTE was three times higher among those who used pills with levonorgestrel and six times higher among those who took pills with drospirenone, desogestrel or gestodene.
But the absolute risk of VTE associated with taking the newer pills is relatively low, about 10 per 10,000 women, according to the University of Copenhagen researchers.
For every 2,000 women who switched from using newer pills to pills with levonorgestrel, there would be one less case of VTE a year.
The study was published online Oct. 26 in the BMJ.
While some doctors may choose to prescribe birth control pills with a lower risk whenever possible, it is crucial not to exaggerate the risk of VTE, Dr. Philip Hannaford of the University of Aberdeen in Scotland, wrote in an accompanying editorial.
"Oral contraceptives are remarkably safe and may confer important long-term benefits in relation to cancer and mortality," he said in a journal news release.
More information
The American College of Obstetricians and Gynecologists has more about birth control pills.
http://news.yahoo.com/newer-pill-may-raise-blood-clot-risk-160805707.html;_ylt=AijdlRhWk74.8JHVs__ZqYzrSLYF;_ylu=X3oDMTRiN3B2bHZhBG1pdANUb3BTdG9yeSBIZWFsdGhTRiBTZXh1YWxIZWFsdGhTU0YEcGtnA2E0MzdjNmY2LWJlYTYtM2RkMy04YWEyLWNhYmE1ODc0MThjZgRwb3MDNwRzZWMDdG9wX3N0b3J5BHZlcgMxODE3MWQ5MC0wMDRmLTExZTEtYmZiZi1jNmY1YzU2YzMxNWU-;_ylg=X3oDMTIydmQxa3A0BGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdANoZWFsdGh8c2V4dWFsIGhlYWx0aARwdANzZWN0aW9ucw--;_ylv=3
import from: 

Tuesday, 8 November 2011

More Evidence Shows Newer Forms of 'Pill' Raise Clot Risk, FDA Says

THURSDAY, Oct. 27 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday said it "remains concerned" that a newer generation of birth control pills may raise the odds for serious blood clots more than older forms of the Pill.
The announcement concerns oral contraceptives containing a newer type of progestin hormone called drospirenone, which includes Bayer's Yaz or Yasmin. According to the FDA, the new study found a higher risk of venous thromboembolisms (VTEs) -- potentially dangerous clots -- in women on the drospirenone-containing pills vs. those on older forms of oral contraceptives.
The FDA-funded review involved the medical histories of more than 800,000 American women, all of whom were on some type of birth control between 2001 and 2008. The study found that women taking the newer oral contraceptives experienced a higher rate of clots than women on older forms of the contraceptive pill.
The review also found that women on two other forms of birth control -- the Ortho Evra patch from Johnson & Johnson and the NuvaRing vaginal ring from Merck -- had a higher rate of clots.
For now, the FDA is not advising that most women switch to another form of contraception. "If your birth control pill contains drospirenone, do not stop taking it without first talking to your health care professional," the agency said. "Contact your health care professional immediately if you develop any symptoms of blood clots, including persistent leg pain, severe chest pain or sudden shortness of breath. If you smoke and are over 35 years of age, you should not take combination oral contraceptives because they increase the risk that you could experience serious cardiovascular events, including blood clots."
Thursday's announcement was not the FDA's first word on this issue, nor is likely to be the last. The agency issued a similar warning in September, and in a statement released Thursday said that, "given the conflicting nature of the findings from six published studies evaluating this risk, as well as the preliminary data from the FDA-funded study," it plans to host a public meeting on the issue on Dec. 8.
The announcement Thursday comes a day after the release of a study in BMJ that also found newer birth control pills were tied to a higher risk for clots.
In that study, researchers reviewed data on all Danish women, aged 15 to 49, who were not pregnant between January 2001 and December 2009. During that time, more than 4,200 first episodes of VTEs occurred.
Women taking birth control pills with a newer progestin hormone had twice the risk of clots compared to those who took the older form of contraceptive pills.
Compared to women who did not use birth control pills, the risk of VTE was three times higher among those who used pills with levonorgestrel and six times higher among those who took pills with drospirenone, desogestrel or gestodene.
But the absolute risk of VTE associated with taking the newer pills remained relatively low, about 10 per 10,000 women, according to the University of Copenhagen researchers.
For every 2,000 women who switched from using newer pills to pills with levonorgestrel, there would be one less case of clots a year.
While some doctors may choose to prescribe birth control pills with a lower risk whenever possible, it is crucial not to exaggerate the risk of VTE, Dr. Philip Hannaford of the University of Aberdeen in Scotland, wrote in an accompanying editorial in the journal.
"Oral contraceptives are remarkably safe and may confer important long-term benefits in relation to cancer and mortality," he said in a journal news release.
Dr. Glenn Jacobowitz, vice chair of the division of vascular surgery at NYU Langone Medical Center in New York City, said: "The information for Yaz is not new. That has recently already been shown in studies to have an increased risk of blood clots than other oral contraceptives. The information on NuvaRing and Ortho Evra would be a new, but similar finding. This is certainly worrisome, particularly for women over age 35 and for smokers."
More information
The American College of Obstetricians and Gynecologists has more about birth control pills.

import from: http://news.yahoo.com/more-evidence-shows-newer-forms-pill-raise-clot-210812820.html;_ylt=AhZmDfsim2c4UUd9xF4zlSvrSLYF;_ylu=X3oDMTRiOW04YjRjBG1pdANUb3BTdG9yeSBIZWFsdGhTRiBTZXh1YWxIZWFsdGhTU0YEcGtnAzJkYWIxYzYwLWY1ODQtMzQ5Ni1iOTQwLTkyMTVhNzMzODkwNQRwb3MDNARzZWMDdG9wX3N0b3J5BHZlcgMwZTQ4MmVjMC0wMTE4LTExZTEtYmZiYS1mZDhlMDA3NjA3ZWI-;_ylg=X3oDMTIydmQxa3A0BGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdANoZWFsdGh8c2V4dWFsIGhlYWx0aARwdANzZWN0aW9ucw--;_ylv=3

Monday, 7 November 2011

Some birth control shows higher clot risk: US

Some birth control products, including contraceptive pills, rings and patches for women, carry a significantly higher risk of blood clot than low-dose medications, US regulators said Thursday.
The US Food and Drug Administration said in its review of studies that have included more than 800,000 women that the higher risks are posed by products such as the pill Yaz, the transdermal Ortho Evra patch, and the NuvaRing vaginal insert.
All three methods are "associated with an increased risk of VTE (deep venous thrombosis) relative to the standard low-dose" pills, the FDA said.
Featured in the study were pills that contain drospirenone, as opposed to another type of progestin known as levonorgestrel. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.
Yaz is the second biggest selling product made by the German pharmaceutical giant Bayer, with 1.56 billion in global sales.
NuvaRing is a once-a-month vaginal insert made by Merck pharmaceuticals, and the weekly Ortho Evra patch is made by Janssen Pharmaceuticals.
The finding about clot risk associated with patches and rings are new and need to be replicated, the FDA said. A full discussion on the matter is scheduled for December.
These "continuous exposure" birth control methods "potentially result in higher sustained exposure to estrogen and hence, increased thromboembolic risk," the FDA warned.
The European Medicines Agency concluded on May 27 that such birth control pills carry a higher risk of venous thromboembolism and that warning labels should be updated accordingly.
However it noted the overall risk of blood clot from any birth control method remains small and stopped short of advising women to stop taking pills containing drospirenone.
The pills have been the focus of numerous lawsuits, including one lodged earlier this year on behalf of a teenager who died from a blood clot allegedly linked to the German chemical and pharmaceutical company Bayer's Yaz contraceptive.
Michelle Pfleger, an 18-year-old college student in North Carolina, died of cardiac arrest last September after taking Yaz, also known as Yasmin or Ocella, to treat acne, according to the complaint.
Two studies out this year in the British Medical Journal found that drugs like Yaz and Yasmin increase the risk of serious blood clots three-fold or two-fold compared to earlier-generation oral contraceptives.
The official Yaz website says the drug is associated with "increased risks of several serious side effects, including blood clots, stroke, and heart attack."
According to Glenn Jacobowitz, vice-chair of the division of vascular surgery at New York University Langone School of Medicine, doctors have been aware of the risks of Yaz and similar pills for some time.
"The information on NuvaRing and Ortho Evra would be a new, but similar finding. This is certainly worrisome, particularly for women over age 35 and for smokers," he said.

import from: http://news.yahoo.com/birth-control-shows-higher-clot-risk-us-222419487.html;_ylt=Am1.MWVKR0MMlYKpwpQ19kDrSLYF;_ylu=X3oDMTRiYWJqZWY4BG1pdANUb3BTdG9yeSBIZWFsdGhTRiBTZXh1YWxIZWFsdGhTU0YEcGtnA2E2N2I1OTI4LTg0OGQtMzY0YS04MzkxLTEzOWQ5ZDQ5OTU1ZgRwb3MDMgRzZWMDdG9wX3N0b3J5BHZlcgMxNDZkZDBiMC0wMTc4LTExZTEtOGVmZC03ZWMwNjRhNjhkNDQ-;_ylg=X3oDMTIydmQxa3A0BGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdANoZWFsdGh8c2V4dWFsIGhlYWx0aARwdANzZWN0aW9ucw--;_ylv=3

Sunday, 6 November 2011

Scientists Identify Gene Linked to Cold Sores

FRIDAY, Oct. 28 (HealthDay News) -- Researchers have identified a certain gene associated with susceptibility to herpes simplex labialis, more commonly known as cold sores.
People who carry this gene may have more frequent and severe outbreaks of the small blister-like lesions that appear around the mouth, the new study said. The researchers noted that their findings could lead to the development of new treatments for the herpes simplex virus type 1, which infects 70 percent of the U.S. population, according to a news release from the Infectious Diseases Society of America.
In the study, investigators identified an area on human chromosome 21 among 618 people from 43 large families where six genes that have been previously linked to cold sores are located. They found one gene in particular, known as C21orf91, was linked to more frequent outbreaks.
"While these findings await confirmation in a larger, unrelated population, these findings could have important implications for the development of new drugs that affect determinants of the cold sore phenotype," study author Dr. John Kriesel and colleagues at the University of Utah School of Medicine in Salt Lake City and the University of Massachusetts Medical School explained in the release.
In an editorial accompanying the study, published online Oct. 28 in the Journal of Infectious Diseases, Australian scientists noted that if the findings are confirmed, more research could also begin to investigate whether this gene also plays a role in genital herpes.
More information
The U.S. National Library of Medicine has more about cold sores.

import from: http://news.yahoo.com/scientists-identify-gene-linked-cold-sores-130804564.html;_ylt=Ajx421GMZGiN6HnVkazGVLnrSLYF;_ylu=X3oDMTRidDNzODloBG1pdANUb3BTdG9yeSBIZWFsdGhTRiBTZXh1YWxIZWFsdGhTU0YEcGtnAzVjOTM4Mjc1LTAzOTUtM2I0MC05NzA4LTdlOGQ4YmZkOTM3YgRwb3MDMQRzZWMDdG9wX3N0b3J5BHZlcgMyN2I5OWE1MC0wMWUxLTExZTEtYjlmYi1kY2JkODUxMjBhODI-;_ylg=X3oDMTIydmQxa3A0BGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdANoZWFsdGh8c2V4dWFsIGhlYWx0aARwdANzZWN0aW9ucw--;_ylv=3

Saturday, 5 November 2011

Program urges smokers switch to smokeless tobacco



In the smoker-heavy state of Kentucky, a cancer center is suggesting something that most health experts won't and the tobacco industry can't: If you really want to quit, switch to smoke-free tobacco.
The James Graham Brown Cancer Center and the University of Louisville are aiming their "Switch and Quit" campaign at the city of Owensboro. It uses print, radio, billboard and other advertising to urge smokers to swap their cigarettes for smokeless tobacco and other products that do not deliver nicotine by smoke.
Supporters say smokers who switch are more likely to give up cigarettes than those who use other methods such as nicotine patches, and that smokeless tobacco carries less risk of disease than cigarettes do.
"We need something that works better than what we have," said Dr. Donald Miller, an oncologist and director of the James Graham Brown Cancer Center, which supports the effort along with the University of Louisville. "This is as reasonable a scientific hypothesis as anybody has come up with and it needs to be tried."
The campaign runs counter to the prevailing opinion of the public health community, which holds that there is no safe way to use tobacco. Federal researchers, however, have begun to at least consider the idea that smokers might be better off going smokeless.
The National Cancer Institute at the National Institutes of Health says on its website that the use of all tobacco products "should be strongly discouraged," and that there is "no scientific evidence that using smokeless tobacco can help a person quit smoking." But this year it approved funding for a study that might provide some of that very evidence.
"Switch and Quit" is directed by Brad Rodu, a professor of medicine at the University of Louisville. He analyzed the 2000 National Health Interview Survey and found that male smokers who switched to smokeless tobacco were more likely to quit smoking than those who used nicotine patches or gum.
"Americans are largely misinformed about the relative risks. ... They think smokeless tobacco is just as dangerous," Rodu said. "This level of misinformation is an enormous barrier to actually accomplishing tobacco-harm reduction because if people believe that the products have equal risk, there's not a real incentive."
The program is funded through Rodu's research money, which includes grants from the tobacco industry. Grants through the University of Louisville are unrestricted, which the program says "ensures the scientific independence and integrity of research projects and activities."
"There's absolutely no influence whatsoever," Rodu said. "I decide, along with my colleagues, how we use the money, for what projects, and this is entirely the case. I would not have a situation where there was some control over the kind of projects I undertake."
Tobacco companies want to market more smokeless tobacco and other cigarette alternatives to make up for falling cigarette sales. Some have introduced "snus" — small pouches like tea bags that users stick between the cheek and gum — and dissolvable tobacco — finely milled tobacco shaped into orbs, sticks and strips.
But they're barred by federal law from explicitly marketing them as less risky than cigarettes — at least for now. That means the "Switch and Quit" program can do something the tobacco industry itself cannot: claim that smokeless tobacco has a health benefit when compared to smoking.
The program says smoking kills about 220 adults a year in and around Owensboro. The state of Kentucky, a leading tobacco grower, has the nation's highest smoking and lung cancer rates.
Owensboro and the surrounding area consume about 3 million cigarettes a week, according to the program. That amounts to well over a pack for every man, woman and child in the community of about 115,000 people.
Owensboro resident Vernon Goode had smoked for about 10 years before he recently traded his Marlboros for dissolvable tobacco tablets. The campaign didn't inspire him to quit, but he said he thought it was a good idea.
"I was just wanting to quit because, you know, I could feel it in my lungs," Goode said. "I'll smoke a cigarette every once in a while, but not very often. I want to quit altogether and I'm just using this right here as I guess what you'd call a stepping stone."
The Owensboro program has raised concerns among some in the public health community who say organizers are claiming smokeless tobacco is a healthier alternative to smoking without approval from the Food and Drug Administration.
A 2009 law gives the FDA authority to evaluate health risks of tobacco products and approve those that could be marketed as safer than what's currently for sale. None have been given the OK yet. The FDA also plans to regulate electronic cigarettes, battery-powered plastic and metal devices that heat a liquid nicotine solution in a disposable cartridge, creating vapor that users inhale.
Matthew Myers, president of the Campaign for Tobacco-Free Kids, called the program "a giant experiment with the people of Owensboro without rules or guidance designed to protect individuals from experimental medicine."
Smokeless tobacco isn't a safe alternative to cigarettes, according to the Centers for Disease Control and Prevention. Health warnings on the products required by the FDA state the same thing.
However, some studies, including a 2007 report from the Royal College of Physicians in London titled "Harm Reduction in Nicotine Addiction," suggest that some smokeless tobacco products are about 90 percent less harmful than cigarettes.
"The worst that you can say about smokeless tobacco is that it's the lesser of two evils," said Dr. Randall Thomas, an oncologist with the Owensboro Medical Health System. The health system, the community's largest employer, is going smoke-free in 2013 and is offering Rodu's program as one of a variety of quit-smoking tools for its employees.
"I don't think we have any problem in telling a person that drinks a six-pack a day that if they could cut it back to two beers a day or two drinks a day that their health risks are greatly reduced," Thomas said. "Finding a way to let people have their nicotine that carries less risk, it's the realistic solution."
The Owensboro program doesn't suggest pharmaceutical nicotine replacement gum or patches. That's because they are regulated to provide very small doses of nicotine and are recommended for only a short period of time, while smokeless tobacco can be used as long as a smoker needs, Rodu said.
Myers, of the Campaign for Tobacco-Free Kids, said more research is needed before anyone should suggest that the nation's 46 million smokers would be better off using smokeless tobacco. In the meantime, he said, there are a host of FDA-approved products that can help people give up smoking.
"There's a right way and a wrong way to determine whether smokeless tobacco can and should be marketed as a way to help people quit," Myers said.
The National Cancer Institute approved funding earlier this year for a nationwide 1,250-person study to look at whether being given a snus product changes the habits of smokers who are not motivated to quit.
The tobacco industry sees smokeless tobacco as its future, said Matthew J. Carpenter, a psychology professor at the Medical University of South Carolina who is conducting the yearlong study.
Carpenter said the snus study will examine what smokers do when given smokeless tobacco. He won't look at the health effects, or advise smokers to use the snus to quit.
"They are probably safer than conventional cigarettes, if for no other reason than you're not burning anything, you're not smoking anything, you're not inhaling any smoke," he said.
"If you compare it to conventional cigarettes, they're probably a little bit better. If you compare it to quitting, they're absolutely worse."
___
Michael Felberbaum can be reached at http://www.twitter.com/MLFelberbaum.

import from: http://news.yahoo.com/program-urges-smokers-switch-smokeless-tobacco-182613157.html